# EDGAR Filing Document

**Accession Number:** 0001534980
**File Stem:** 0001062993-23-000628
**Filing Date:** 2023-1
**Character Count:** 9993
**Document Hash:** b48eee605ec3cd9418997e16d273f549
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-000628.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001062993-23-000628

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230104

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kummeth Charles R.
- **CENTRAL INDEX KEY:** 0001534980

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 23515539

**MAIL ADDRESS:**
- **STREET 1:** 425 MARTINGALE ROAD
- **STREET 2:** SUITE 1000
- **CITY:** SCHAUMBURG
- **STATE:** IL
- **ZIP:** 60173-2213
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 6123798854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kummeth Charles R.<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-04 |  | M |  | 407364 | A | $26.65 | 1368976<sup>(1)</sup> | D |  |
| Common Stock | 2023-01-04 |  | F |  | 255837 | D | $84.39 | 1113139 | D |  |
| Common Stock |  |  |  |  |  |  |  | 400 | I | By Step-Son |
| Common Stock |  |  |  |  |  |  |  | 400 | I | By Step-Daughter |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | $26.65 | 2023-01-04 |  | M |  |  | 407364 | <sup>(2)</sup> | 2023-08-18 | Common Stock | 407364 | $0 | 616676 | D |  |
| Stock Options (Right to Buy) | $31.2625 |  |  |  |  |  |  | <sup>(2)</sup> | 2024-08-09 | Common Stock | 779084 |  | 779084 | D |  |
| Stock Options (Right to Buy) | $44.33 |  |  |  |  |  |  | <sup>(2)</sup> | 2025-08-08 | Common Stock | 361336 |  | 361336 | D |  |
| Stock Options (Right to Buy) | $44.33 |  |  |  |  |  |  | <sup>(2)</sup> | 2025-08-08 | Common Stock | 240888 |  | 240888 | D |  |
| Stock Options (Right to Buy) | $47.6025 |  |  |  |  |  |  | <sup>(2)</sup> | 2026-08-07 | Common Stock | 342900 |  | 342900 | D |  |
| Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 52900 |  | 52900 | D |  |
| Stock Options (Right to Buy) | $94.52 |  |  |  |  |  |  | <sup>(5)</sup> | 2029-08-15 | Common Stock | 1200000 |  | 1200000 | D |  |
| Stock Options (Right to Buy) | $47.6025 |  |  |  |  |  |  | <sup>(6)</sup> | 2026-08-07 | Common Stock | 228600 |  | 228600 | D |  |
| Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 51516 |  | 51516 | D |  |
| Stock Options (Right to Buy) | $66.9675 |  |  |  |  |  |  | <sup>(7)</sup> | 2027-08-05 | Common Stock | 299768 |  | 299768 | D |  |
| Stock Options (Right to Buy) | $66.9675 |  |  |  |  |  |  | <sup>(8)</sup> | 2027-08-05 | Common Stock | 153180 |  | 153180 | D |  |
| Stock Options (Right to Buy) | $66.9675 |  |  |  |  |  |  | <sup>(9)</sup> | 2027-08-05 | Common Stock | 66600 |  | 66600 | D |  |
| Stock Options (Right to Buy) | $66.9675 |  |  |  |  |  |  | <sup>(10)</sup> | 2027-08-05 | Common Stock | 66600 |  | 66600 | D |  |
| Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(11)</sup> | <sup>(11)</sup> | Common Stock | 32064 |  | 32064 | D |  |
| Stock Options (Right to Buy) | $120.455 |  |  |  |  |  |  | <sup>(11)</sup> | 2028-08-06 | Common Stock | 125260 |  | 125260 | D |  |
| Stock Options (Right to Buy) | $120.455 |  |  |  |  |  |  | <sup>(12)</sup> | 2028-08-06 | Common Stock | 83504 |  | 83504 | D |  |

---

### Footnotes:

(1) Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024.

(2) Fully exercisable.

(3) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(4) 17,632 shares vest on each of 8/15/2023 and 8/15/2025, and 17,636 shares vest on 8/15/2024.

(5) 600,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(6) Options to purchase 57,152 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 57,148 shares vest on each of 8/7/2022 and 8/7/2023.

(7) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(8) Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.

(9) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

(10) Options to purchase 22,200 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.

(11) Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(12) Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.

**Remarks:**
On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.

**Signature:** /s/ Brenda S. Furlow, Attorney-in-Fact  
**Date:** 2023-01-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**